

factsheet | About Medicines for Europe



About Medicines for Europe

Medicines for Europe (formerly EGA) represents the generic, biosimilar and value added medicines industries across Europe. Its vision is to provide sustainable access to high quality medicines for Europe, based on 5 important pillars: patients, quality, value, sustainability and partnership. Its members employ 160,000 people at over 350 manufacturing and R&D sites in Europe, and invest up to 17% of their turnover in medical innovation.

Medicines for Europe member companies across Europe are both increasing access to medicines and driving improved health outcomes. They play a key role in creating sustainable European healthcare systems by continuing to provide high quality, effective generic medicines, whilst also innovating to create new biosimilar medicines and bringing to market value added medicines, which deliver better health outcomes, greater efficiency and/or improved safety in the hospital setting for patients.

For more information please follow us at www.medicinesforeurope.com and on Twitter [@medicinesforEU](https://twitter.com/medicinesforEU).

The Generic Medicines Group



The Generic Medicines Group is a sector group of **Medicines for Europe**, representing the generic medicines developers and manufacturers, which provide high-quality cost-competitive medicines to millions of patients in Europe and around the world. Generic medicines account today for 56% of all prescribed medicines but for only 22% of the pharmaceutical expenditure, or 2-4% of total healthcare costs, in Europe. The generic medicines industry has increased access to medicines by over 100% in 7 key therapeutic areas without increasing the overall treatment cost across Europe.

The Biosimilar Medicines Group



The Biosimilar Medicines Group is a sector group of **Medicines for Europe** representing the leading companies developing, manufacturing and/or marketing biosimilar medicines across Europe. With more than 10 years of positive patient treatment experience and 20 products successfully launched, biosimilar medicines provide today a huge opportunity to deliver significantly improved access to modern therapies for millions of European patients in both chronic and acute care. Our members bring competition to the biological medicines market, thereby increasing access to highly innovative treatments to patients, in Europe and around the world, and supporting the sustainability of the European healthcare systems.

The Value Added Medicines Group



The Value Added Medicines Group is a sector group of **Medicines for Europe** which aims at optimizing, rethinking and reinventing medicines based on known molecules and are an answer to improve care delivery. The Value Added Medicines Group adopts a complementary perspective compared to the other **Medicines for Europe** sector groups: by tackling the targeted portion of patients' needs that remain unmet to this day, delivering additional improvement to the healthcare community as a whole.

Medicines for Europe Membership

MEDICINES FOR EUROPE MEMBER COMPANIES

Accord Healthcare
Alfred E. Tiefenbacher
Alkaloid
Allergan
Apotex Europe
Baxalta
Boehringer Ingelheim
Cipla Europe
Combino Pharm
Consilient Health

Egis Pharmaceuticals
Farmoz
Fresenius Kabi
Gedeon Richter
Helm
Infarco
Jadran Galenski Laboratorij
KRKA
Lupin
Medochemie

Merck Serono
Mylan
Polpharma
Sandoz
Sanofi Generics
Sopharma
Stada
Synthon
Teva Europe

MEDICINES FOR EUROPE AFFILIATE MEMBER COMPANIES

Acino Pharma
AMCo
Anapharm Europe
Billev Pharma

Disphar
Farmaprojects
Glenmark Generics
JSC "Farmak"

Hetero
PharOS

NATIONAL ASSOCIATIONS FULL MEMBERS

AESEG (Spain)
APOGEN (Portugal)
AssoGenerici (Italy)
BGMA (United Kingdom)

BOGIN (Netherlands)
FeBelGen (Belgium)
GEMME (France)
IEIS (Turkey)

IGL (Denmark)
Pro Generika (Germany)
PZPPF (Poland)

NATIONAL ASSOCIATIONS AFFILIATE MEMBERS

APM GR (Romania)
BGPharma (Bulgaria)
CAFF (Czech Republic)

FGA (Finland)
FGL (Sweden)
GE (Hungary)

HEA (Ireland)
Intergenerika (Switzerland)
OEGV (Austria)